VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

Cancer Research

Volumn 64, Issue 21, 2004, Pages 7822-7835

  Woolard, Jeanette ^a   Wang, Wen Ying ^a   Bevan, Heather S ^a   Qiu, Yan ^a   Morbidelli, Lucia ^b   Pritchard Jones, Rowan O ^a   Cui, Tai Gen ^a,c   Sugiono, Marto ^a,d   Waine, Elizabeth ^a,d   Perrin, Rachel ^a   Foster, Rebecca ^a   Digby Bell, Jonathon ^a   Shields, Jacqueline D ^a   Whittles, Cheryl E ^a   Mushens, Rosey E ^e   Gillatt, David A ^d   Ziche, Marina ^b   Harper, Steven J ^a   Bates, David O ^a,f  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SIENA   (Italy)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d Bristol Institute   (United Kingdom)

^e SOUTHMEAD HOSPITAL   (United Kingdom)

^f Preclinical Veterinary School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CELL GROWTH FACTOR 165B; VASCULOTROPIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORNEA; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MESENTERY; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RABBIT; RAT; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION; ANIMAL; CHO CELL; DRUG ANTAGONISM; GENETICS; HAMSTER; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; RNA SPLICING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RABBITS; RATS; RNA SPLICING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 7444240909     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0934     Document Type: Article

References (56)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature (Lond.) 2000;407:249-57.
2. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66.
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-4.
4. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
5. Neufeld G, Cohen T, GitayGoren H, et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996;15:153-8.
6. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39:225-37.
7. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-97.
8. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
9. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (Lond.) 1996;380:435-9.
10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond.) 1996;380:439-42.
11. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
12. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62.
13. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
14. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
15. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia- response element in the vascular endothelial growth factor promoter causes motor neuron degenerarion. Nat Genet 2001;28:131-8.
16. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Investig 2003;112:1655-65.
17. Bachelder RE, Wendt MA, Mercuric AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-6.
18. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40.
19. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (Lond.) 2002;417:954-8.
20. Foster RR, Hole R, Anderson K, et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003;284:F1263-73.
21. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol 1993;264:C995-1002.
22. Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak HF, Rosen S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 1995;154:576-9.
23. Kuroda M, Oka T, Oka Y, et al. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 1995;80:3196-200.
24. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457-61.
25. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62:4123-31.
26. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271:7788-95.
27. Saleem MA, O'Hare MJ, Reiser J, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002;13:630-8.
28. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993;15:532-4, 536-7.
29. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide-synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-34.
30. Wang W-Y, Whittles CE, Harper SJ, Bates DO. An adenovirus mediated gene transfer model of angiogenesis in rat mesentery. Microcirculation 2004;11:361-75.
31. Norrby K, Jakobsson A, Sorbo J. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;52:195-206.
32. Ancelin M, Buteau-Lozano H, Meduri G, et al. A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci USA 2002;99:6023-8.
33. Huez I, Bornes S, Bresson D, Creancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 2001;15:2197-210.
34. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999;35:133-7.
35. 165b) mRNA and protein. Am J Physiol Renal Physiol 2004;286:F767-73.
36. Yang S, Xin X, Zlot C, et al. Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler Thromb Vasc Biol 2001;21:1934-40.
37. Gupta K, Kshirsagar S, Li W, et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999;247:495-504.
38. Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000;275:5096-103.
39. Bates DO, Heald RI, Curry FE, Williams B. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol 2001;533:263-72.
40. Becker PM, Verin AD, Booth MA, Liu F, Birukova A, Garcia JG. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2001;281:L1500-11.
41. Whittles CE, Pocock TM, Wedge SR, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 2002;9:513-22.
42. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000;83:63-8.
43. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
44. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.) 1992;359:843-5.
45. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
46. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-86.
47. Autiero M, Waltenberger J, Communi D, et al. Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43.
48. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16:2684-98.
49. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002;12:325-34.
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
51. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-90.
52. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999;13:537-45.
53. Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-8.
54. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 1998;16:319-28.
55. Otani A, Slike BM, Dorrell MI, et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 2002;99:178-83.
56. Jin Y, Pasumarthi KB, Bock ME, Lytras A, Kardami E, Cattini PA. Cloning and expression of fibroblast growth factor receptor-1 isoforms in the mouse heart: evidence for isoform switching during heart development. J Mol Cell Cardiol 1994;26:1449-59.